TWD 55.0
(-3.68%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 218.25 Million TWD | 6.5% |
2022 | 205.57 Million TWD | 2.79% |
2021 | 200 Million TWD | 22.98% |
2020 | 162.62 Million TWD | 4.02% |
2019 | 156.34 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 58.31 Million TWD | 8.58% |
2024 Q1 | 53.7 Million TWD | -6.91% |
2023 Q4 | 57.68 Million TWD | -3.36% |
2023 FY | 218.93 Million TWD | 6.5% |
2023 Q3 | 59.69 Million TWD | 13.76% |
2023 Q2 | 52.46 Million TWD | 6.89% |
2023 Q1 | 49.08 Million TWD | -11.47% |
2022 FY | 205.57 Million TWD | 2.79% |
2022 Q4 | 55.44 Million TWD | 0.0% |
2021 FY | 200 Million TWD | 22.98% |
2020 FY | 162.62 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BIONET Corp. | 553.58 Million TWD | 60.574% |
DIVA Laboratories, Ltd. | 158.62 Million TWD | -37.595% |
Welgene Biotech Co.,Ltd. | 123.97 Million TWD | -76.047% |
Puriblood Medical Co., Ltd. | 56.92 Million TWD | -283.4% |
TFBS Bioscience Inc. | 77.82 Million TWD | -180.428% |